Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics
- PMID: 17361328
- DOI: 10.1007/s11060-007-9365-8
Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics
Abstract
To determine the frequency of human telomerase reverse transcriptase (hTERT) catalytic fraction expression and its association with clinical and demographic characteristics of the patient, as well as with the expression of CD34 and proliferating cell nuclear antigen (PCNA) indexes on adenohypophyseal hormone tissues. A transverse study was realized with 49 cases of hypophyseal adenoma with analysis type cases and controls. The different adenohypophyseal hormones [prolactin (PRL), growth hormone (GH), follicle stimulating hormone, luteinizing hormone, thyroid gland stimulant hormone, adrenocorticotropic hormone (ACTH)], the catalytic fraction of the telomerase hTERT, the PCNA index and the CD34 density were determined by means of immunohistochemical techniques. The clinical, demographic and histopathological characteristics of the patients with and without hTERT expression were compared by means of Pearson's Chi-squared, Fisher's exact test and Mann-Whitney's U. Twenty-eight point six percent of the adenomas had positive expression for hTERT. The variables significantly correlated with hTERT's expression were younger age of presentation, diagnostic of adenoma producer, higher PCNA index, higher CD34 density, increased GH on serum and the expression on PRL tissue, GH and ACTH. Tobacco history had a negative association with hTERT's expression. The telomerase could be a marker of cellular proliferation associated with angiogenesis and hormonal activity. Evaluation of these variables could provide information about their biological behavior.
Similar articles
-
Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma.Folia Histochem Cytobiol. 2006;44(1):37-41. Folia Histochem Cytobiol. 2006. PMID: 16584090
-
[Immunohistochemistry for pituitary hormones and Ki-67 in growth hormone producing pituitary adenomas].Rev Med Chil. 2008 Jul;136(7):831-6. Epub 2008 Sep 4. Rev Med Chil. 2008. PMID: 18949157 Spanish.
-
Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.Eur J Endocrinol. 2006 May;154(5):753-8. doi: 10.1530/eje.1.02107. Eur J Endocrinol. 2006. PMID: 16645024
-
Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.Mod Pathol. 2002 Nov;15(11):1205-12. doi: 10.1097/01.MP.0000036342.73003.55. Mod Pathol. 2002. PMID: 12429800
-
Pituitary adenomas. An immunohistochemical study of hormone production and chromogranin localization.Am J Pathol. 1984 Sep;116(3):464-72. Am J Pathol. 1984. PMID: 6089568 Free PMC article.
Cited by
-
Telomere length and telomerase expression in pituitary tumors.J Endocrinol Invest. 2015 Nov;38(11):1243-6. doi: 10.1007/s40618-015-0298-3. Epub 2015 May 8. J Endocrinol Invest. 2015. PMID: 25952298
-
Telomerase and the endocrine system.Nat Rev Endocrinol. 2011 Mar 29;7(7):420-30. doi: 10.1038/nrendo.2011.52. Nat Rev Endocrinol. 2011. PMID: 21448143 Review.
-
TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas.J Neurooncol. 2019 Jan;141(1):131-138. doi: 10.1007/s11060-018-03016-8. Epub 2018 Nov 3. J Neurooncol. 2019. PMID: 30392088
-
Telomerase expression in clinically non-functioning pituitary adenomas.Endocrine. 2021 Apr;72(1):208-215. doi: 10.1007/s12020-020-02524-w. Epub 2020 Oct 22. Endocrine. 2021. PMID: 33090306
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous